 |
 | Home | Contact Us | FAQ | Search & Site Map | Link to Us |
 | Sign In | Join | Other 45 Sites in Network |
Medical Forum / General / Alternative / May 2006Vaccines *Truth*
Ohh looky what I found! A repost: http://groups.google.com/group/misc.health.alternative/msg/cd4fd6298e7dbe19?&q=V accine+Ingredients+-+A+difference+of+opinion 2001 Sep;124(Pt 9):1821-31 Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Gherardi RK, Coquet M, Cherin P, Belec L, Moretto P, Dreyfus PA, Pellissier JF, Chariot P, Authier FJ. Equipe mixte INSERM E 0011/Universite Paris XII, France. romain.gherardi@hmn.ap-hop-paris.fr Macrophagic myofasciitis (MMF) is an emerging condition of unknown cause, detected in patients with diffuse arthromyalgias and fatigue, and characterized by muscle infiltration by granular periodic acid-Schiff's reagent-positive macrophages and lymphocytes. Intracytoplasmic inclusions have been observed in macrophages of some patients. To assess their significance, electron microscopy was performed in 40 consecutive cases and chemical analysis was done by microanalysis and atomic absorption spectrometry. Inclusions were constantly detected and corresponded to aluminium hydroxide, an immunostimulatory compound frequently used as a vaccine adjuvant. A lymphocytic component was constantly observed in MMF lesions. Serological tests were compatible with exposure to aluminium hydroxide-containing vaccines. History analysis revealed that 50 out of 50 patients had received vaccines against hepatitis B virus (86%), hepatitis A virus (19%) or tetanus toxoid (58%), 3-96 months (median 36 months) before biopsy. Diffuse myalgias were more frequent in patients with than without an MMF lesion at deltoid muscle biopsy (P < 0.0001). Myalgia onset was subsequent to the vaccination (median 11 months) in 94% of patients. MMF lesion was experimentally reproduced in rats. We conclude that the MMF lesion is secondary to intramuscular injection of aluminium hydroxide-containing vaccines, shows both long-term persistence of aluminium hydroxide and an ongoing local immune reaction, and is detected in patients with systemic symptoms which appeared subsequently to vaccination. PMID: 11522584 [PubMed - indexed for MEDLINE] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&... uids=12184366&dopt=Abstract Vaccine 2002 May 31;20 Suppl 3:S5-6 Related Articles, Links Macrophagic myofasciitis: a summary of Dr. Gherardi's presentations. Brenner A. Rhevmatological Services, Inc., Framington, MA 01702, USA. alan...@aol.com Dr. R.K. Gherardi presented two papers at the symposium, detailing his researches into a proposed new clinical entity which he has entitled Macrophagic Myofasciitis (MMF). In his first paper he described the histopathologic and immunologic characteristics of the condition, and in the second, the clinical and serologic features. Dr. Gherardi believes that MMF, a syndrome of ascending myalgias, fatigue and diffuse musculoskeletal pain, may be related to a chronic immune response to aluminum granulomas persisting at the sites of prior immunization with aluminum adjuvated vaccines. PMID: 12184366 [PubMed - indexed for MEDLINE] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&... uids=11910509&dopt=Abstract Pediatr Dev Pathol 2002 Mar-Apr;5(2):151-8 Related Articles, Links Aluminum phagocytosis in quadriceps muscle following vaccination in children: relationship to macrophagic myofasciitis. Lacson AG, D'Cruz CA, Gilbert-Barness E, Sharer L, Jacinto S, Cuenca R. Departments of Pediatrics and Pathology, University of South Florida at All Children's Hospital, 801 Sixth Street South 7020, St. Petersburg, FL 33731, USA. Macrophagic myofasciitis (MMF) is a rare, seemingly emerging entity among adult patients in France. We encountered two children with the first two cases of MMF in North America. A 5-year-old male with chronic intestinal pseudo-obstruction required nighttime parenteral nutrition. Abnormal pupillary reflexes and urinary retention suggested a diffuse dysautonomia, which prompted a neurological diagnostic work-up. A 3-year-old child had developmental delay and hypotonia. Both children received age-appropriate immunizations. Quadriceps muscle biopsy from each child showed the typical patchy, cohesive centripetal infiltration of alpha-1-antitrypsin+, alpha-1-antichymotrypsin+, CD68+, PAS+, CD1a-, S-100-, factor XIII- granular macrophages with adjacent myofiber atrophy, dilated blood vessels, and mild endomysial and perimysial fibrosis. No myonecrosis was observed and no discrete granulomas were seen. A single aluminum peak was demonstrated on energy dispersive X-ray microanalysis. The etiology of the clinical symptoms in these cases and in cases reported as MMF remains intriguing. Despite numerous stains to demonstrate organisms, most infectious causes leading to macrophage activation were ruled out. These cases are being reported to increase awareness of this condition and to encourage a systematic epidemiologic and clinicopathologic study in North America. PMID: 11910509 [PubMed - indexed for MEDLINE] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&... uids=11335699&dopt=Abstract Brain 2001 May;124(Pt 5):974-83 Related Articles, Links Central nervous system disease in patients with macrophagic myofasciitis. Authier FJ, Cherin P, Creange A, Bonnotte B, Ferrer X, Abdelmoumni A, Ranoux D, Pelletier J, Figarella-Branger D, Granel B, Maisonobe T, Coquet M, Degos JD, Gherardi RK. Groupe d'Etudes et de Recherches sur le Muscle et le Nerf (GERMEN, EA Universite Paris XII-Val de Marne), Faculte de Medecine de Creteil, Departement de Pathologie, Hopital Henri Mondor, AP-HP, Creteil, France. auth...@univ-paris12.fr Macrophagic myofasciitis (MMF), a condition newly recognized in France, is manifested by diffuse myalgias and characterized by highly specific myopathological alterations which have recently been shown to represent an unusually persistent local reaction to intramuscular injections of aluminium-containing vaccines. Among 92 MMF patients recognized so far, eight of them, which included the seven patients reported here, had a symptomatic demyelinating CNS disorder. CNS manifestations included hemisensory or sensorimotor symptoms (four out of seven), bilateral pyramidal signs (six out of seven), cerebellar signs (four out of seven), visual loss (two out of seven), cognitive and behavioural disorders (one out of seven) and bladder dysfunction (one out of seven). Brain T(2)-weighted MRI showed single (two out of seven) or multiple (four out of seven) supratentorial white matter hyperintense signals and corpus callosum atrophy (one out of seven). Evoked potentials were abnormal in four out of six patients and CSF in four out of seven. According to Poser's criteria for multiple sclerosis, the diagnosis was clinically definite (five out of seven) or clinically probable multiple sclerosis (two out of seven). Six out of seven patients had diffuse myalgias. Deltoid muscle biopsy showed stereotypical accumulations of PAS (periodic acid-Schiff)-positive macrophages, sparse CD8+ T cells and minimal myofibre damage. Aluminium-containing vaccines had been administered 3-78 months (median = 33 months) before muscle biopsy (hepatitis B virus: four out of seven, tetanus toxoid: one out of seven, both hepatitis B virus and tetanus toxoid: two out of seven). The association between MMF and multiple sclerosis-like disorders may give new insights into the controversial issues surrounding vaccinations and demyelinating CNS disorders. Deltoid muscle biopsy searching for myopathological alterations of MMF should be performed in multiple sclerosis patients with diffuse myalgias. PMID: 11335699 [PubMed - indexed for MEDLINE] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&... uids=10847840&dopt=Abstract Science 2000 May 26;288(5470):1323-4 Related Articles, Links Public health. Aluminum is put on trial as a vaccine booster. Malakoff D. Publication Types: News PMID: 10847840 [PubMed - indexed for MEDLINE] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&... uids=9302736&dopt=Abstract Vaccine 1997 Aug-Sep;15(12-13):1314-8 Related Articles, Links In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. Flarend RE, Hem SL, White JL, Elmore D, Suckow MA, Rudy AC, Dandashli EA. Department of Physics, Purdue University, West Lafayette, IN 47907, USA. Aluminium hydroxide (AH) and aluminium phosphate (AP) adjuvants, labelled with 26Al, were injected intramuscularly (i.m.) in New Zealand White rabbits. Blood and urine samples were collected for 28 days and analysed for 26Al using accelerator mass spectrometry to determine the absorption and elimination of AH and AP adjuvants. 26Al was present in the first blood sample (1 h) for both adjuvants. The area under the blood level curve for 28 days indicates that three times more aluminium was absorbed from AP adjuvant than AH adjuvant. The distribution profile of aluminium to tissues was the same for both adjuvants (kidney > spleen > liver > heart > lymph node > brain). This study has demonstrated that in vivo mechanisms are available to eliminate aluminium-containing adjuvants after i.m. administration. In addition, the pharmacokinetic profiles of AH and AP adjuvants are different. PMID: 9302736 [PubMed - indexed for MEDLINE] http://brain.oxfordjournals.org/cgi/content/abstract/124/9/1821 I notice you were very selective in the papers you posted - here's the other side of the story. The side that in your dishonesty, you chose not to present: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=16282928&query_hl=14&itool=pubmed_docsum "At present, there are no data to conclude that childhood vaccines, and in particular hepatitis B vaccine, pose a serious health risk or justify a change in current immunization practice." In reference to the risks of vaccines in regards to autism, thimerasol, leukemia and macrophagic myofasciitis. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=16243223&query_hl=14&itool=pubmed_docsum Macrophagic myofasciitis is extremely rare, and limited to people of French origin, suggesting that the disease is a result of genes. Evidence for a genetic link is further supported by this article, using rats: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=16616846&query_hl=14&itool=pubmed_docsum Macrophagic myofasciitis may not be due to aluminum at all: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=15903029&query_hl=14&itool=pubmed_docsum And at the end of the day macrophagic myofasciitis causes minor muscle pain and muscle fatigue. It's etiology (cause) is unknown, and is observed in both vaccinated and unvaccinated people. Even if it is directly caused by vaccination, who really cares? If given a choice between some minor pain verses polio, hepatitis, or any of the other multitude of diseases we vaccinate against, I'll take the muscle pain. Lets not forget - I, nor anyone else who is pro-vaccine, has ever claimed that vaccination is without risk. The thing is, the risk and consequences of not being vaccinated far outweigh any known, or imagined risk. Bryan I've always been curious to know... could you explain to me why it is felt necessary to give the HepB vaccine on the day of birth? Why the rush? Shouldn't parents be given a chance to get to know their babies' personalities before giving such a questionable shot? Sure you've provided evidence that there are no causes for concern, but then others like Jan have given evidence that there *IS* cause for concern. To me, a study showing no cause for concern does not negate one showing cause for concern unless it specifically and fully addresses the reasons that are of concern. > I notice you were very selective in the papers you posted - here's the > other side of the story. The side that in your dishonesty, you chose [quoted text clipped - 29 lines] > consequences of not being vaccinated far outweigh any known, or imagined > risk. In your opinion. My opinion differs. Max. > I've always been curious to know... could you explain to me why it is > felt necessary to give the HepB vaccine on the day of birth? Why the > rush? Shouldn't parents be given a chance to get to know their babies' > personalities before giving such a questionable shot? Sure you've I'm not sure what you're getting at here but it doesn't come across well. > provided evidence that there are no causes for concern, but then others > like Jan have given evidence that there *IS* cause for concern. To me, > a study showing no cause for concern does not negate one showing cause > for concern unless it specifically and fully addresses the reasons that > are of concern. In case you haven't been paying attention the risk/benefit analysis falls on the side of vaccination. Sure some kids get to die, or have complications, but this number is far far smaller than results from non-vaccination. >> I've always been curious to know... could you explain to me why it is >> felt necessary to give the HepB vaccine on the day of birth? Why the >> rush? Shouldn't parents be given a chance to get to know their babies' >> personalities before giving such a questionable shot? Sure you've > > I'm not sure what you're getting at here but it doesn't come across well. Hopefully..this repost will explain it to you. hep B vaccines This response submitted by posted in other forum on 8/11/99. Email Address: This is the statement I sent to every member of the Government Reform Committee who will oversee the hepatitis B vaccine hearings. You have permission to use any part of it and my name as a District Health Services Coordinator (Registered Professional Nurse) who is very concerned with what I am witnessing in the children coming into our schools. This statement is also supported by the Missouri Central District School Nurse Association. I hope this may help in some small way. Thank you so very much for all you do. All the nurses in my district will be praying for you on Tuesday. Thank you for having the courage to fight for the health of our children. Subject: Hepatitis B Vaccine: School Nurse Perspective This is a school nursing perspective for the congressional hearings on May 18 regarding the safety of the hepatitis B vaccine that is being mandated for newborns and now older children in America. Our Central District School Nurse Association asks you to please consider the following information and submit it into the congressional testimony. We continually see more and more damaged children entering our schools, and are very concerned that a major portion of that damage is due to the hepatitis B vaccine's assault on the newborn neurological and immune system. I am a registered professional nurse and the district health services coordinator for a large school district. I am writing on behalf of all the school nurses in our district. We have very grave concerns about the hepatitis B vaccine. For the past three or four years our school districts have noted a significant increase in the number of children entering school with developmental disorders, learning disabilities, attention deficit disorders and/or serious chronic illness such as diabetes, asthma and seizure disorders. Each of the past four years has been worse than the year before. There is only one common thread we can identify in all these children: they are the children who received the first trial hepatitis B injections as newborns in the early 1990s. As the hepatitis B compliance rate in newborns has gone up in our community, so has the percentage of damaged children. This is very alarming. Because of having so many damaged children we have tried to find the long term clinical trials that ruled this vaccine "safe and effective". We discovered through an exhaustive Medline search that the FDA based its decision to approve hepatitis B vaccine for administration in the first hours of a newborn baby's life upon clinical trials and upon post-marketing surveillance studies in which patients and their doctors were asked to report any adverse effects they noticed within 4-5 days after each injection [4 days for SmithKline and 5 days for Merck]. The problems being reported in increasing numbers as occurring after hepatitis B vaccination appear to be autoimmune and neurological in origin. Such problems take weeks to months to produce noticeable symptoms, and cannot be spotted in a 4-5 day observation period. These are the only clinical studies that have been done by Merck or SmithKline. There is not one long-term study that we could find. The CDC and FDA have no idea what the long term effects will be on the newly developing neurological and immune systems of the infants who are injected with this vaccine. They seem to only be concerned with denying the connection between these damaged children and the hepatitis B shot they received within a few hours of birth. The CDC even admits the lack of study and states they do not even know how long the vaccine will be effective. We found this amazing since the vaccine was developed for a population at risk for hepatitis B: IV drug users, high risk medical professionals and those who are involved in high risk sexual practices. In 1950 (before mass immunizations began), the USA had the third lowest infant mortality rate in the world. By 1986, the USA dropped to 17th place. In 1995 the USA dropped to 23rd and now the USA has dropped to the appalling position of 24th in the health of its children (but the USA is now first in vaccine compliance through government mandates). Does this make you nervous too? The elementary grades are overwhelmed with children who have symptoms of neurological and/or immune system damage: epilepsy, seizure disorders, various kinds of palsies, autism, mental retardation, learning disabilities, juvenile-onset diabetes, asthma, vision / hearing loss, and a multitude of new conduct/behavior disorders. We have come to believe the hepatitis B vaccine is an assault on a newborns developing neurological and immune system. Vaccines are supposed to be making us healthier, however, in twenty five years of nursing I have never seen so many damaged, sick kids. Something very, very wrong is happening to our children. The census of ill children seen in our health rooms each day has increased by 300% in only four years. It had remained relatively constant in all the years before. In our last regional school nurse meeting we discussed whether the combination of so many viruses at one time (hepatitis B vaccine at the same time of the DPT, OPV and MMR) is causing the infants immune system to be overwhelmed and unable to mount a sufficient defense response. We are advocating clinical studies to determine: Is the combination of all these viruses at one time an assault on an infant's immune and neurological system that increases the chances for adverse reaction AND what are the long-term neurological and immune system responses to these vaccines. We are all continuing to research this issue and will be happy to share the many resources we have found with you. I hope you will do the same as you open up this issue. We (nurses, principals and teachers) have talked many times about the possible cause(s) of the continuing increase in pervasive developmental disorders (PDD), such as autism. From the literature we have found, we should expect a rate for PDD of about 1 in 10,000. In our community the rate in Kindergarten, 1st and 2nd grade is more like 1 in 150. The teaching staff is overwhelmed. As school nurses, we have had many parents calling and asking how they can exempt their children from the hepatitis B vaccination (HPB). Many of them have spent long hours in study and research perplexed over this issue. For the past six months we have been studying documents, books and research articles published by internationally respected doctors and scientists that cause us grave concern. You must understand that we began this study to reassure our parents and show them the truth about how safe vaccines are. Unfortunately, our sincere, honest, dedicated study has caused a complete reversal of our once strongly held beliefs. Instead of being able to reassure the parents, we have found ourselves being drawn deeper and deeper into this unbelievable controversy over vaccines that is raging among physicians, scientists, researchers, parents, and the government. We pray you will have the courage to shine the light on this controversy through these hepatitis B hearings. My daughter's own experience with the hepatitis B vaccine made me much more open-minded to the information we have been receiving from parents, teachers and other nurses in our community. I personally have had to research this on my own to determine if I have been enforcing a policy that is actually harming more children than it will ever help. I have spent countless hours reading books, vaccine-hearing testimony, research papers, medical journal articles and Internet web-sites from around the world. I did not come to my decision easily or lightly, I assure you. Twenty-five years of total belief in something does not shake that easily. I have repeated the well-rehearsed refrain "Be Wise & Immunize" thousands of times during those years and reassured countless parents that they were doing the right thing by vaccinating their precious children . . . even the ones who came to me with serious doubts and reservations. I will now have to live with that. We are all now faced with a moral dilemma: will we protect the "sacred cow of conventional vaccine philosophy" or will we stand up and speak out for the "health and well being of innocent children"? We choose children. We wonder, which will our government choose? Because the hepatitis B vaccine was developed for those at risk of disease, including IV drug users and sexually promiscuous individuals, efforts to require administration of the vaccine to most, if not all of the U.S. population is very controversial. The increasing number of adverse reaction reports connected with this vaccine exacerbates the controversy. The controversy stems to a great extent from our lack of understanding of the mechanisms of the immune response to the hepatitis B surface antigen and lack of long term follow-up of individuals who have received the vaccine. In a January 27, 1999 press release, the National Vaccine Information Center (NVIC) released figures which show that the number of hepatitis B vaccine-associated serious adverse event and death reports in American children under the age of 14 outnumber the reported cases of hepatitis B disease. During our research we discovered a copy of the grant proposal submitted recently to the National Institute of Health by Dr. B. S. Dunbar, who has worked in autoimmunity and vaccine development for over twenty years and was honored two years ago by the National Institute of Health. Dr. Dunbar is working with a team of veteran vaccine researchers from all over the world. Their grant is requested for the purpose of studying the hypothesis that: hepatitis B recombinant vaccine does cause adverse autoimmune reactions in genetically susceptible individuals. This study will also provide new insights into the predictability of determining adverse side effects of the hepatitis B vaccine in individuals at risk as related to their histocompatability subtypes. Their study of auto-immune diseases/symptoms caused by the hepatitis B vaccine include: lupus erythematosus, rheumatoid arthritis, vascular disorders, Guillain Barre syndrome, demyelinating disorders such as optic neuritis (blindness), Bell's palsy, demyelinating neuropathy (multiple developmental disorders), multiple sclerosis, diabetes mellitus and chronic fatigue syndrome to mention the most common. This group of internationally respected vaccine researchers headed up by Dr. Dunbar also point out that, "The studies (for the approval of HPB) were not designed to assess serious, rare adverse events; the total number of recipients were too small; and the follow-up was too short to detect rare or delayed, serious, adverse reactions." Finally they point out that "overall the number of examples of adverse neurologic outcomes following receipt of hepatitis B vaccine are of concern, particularly those resulting in demyelinating neurologic disease." They continue, "In view of these observations. . . it is medically crucial to evaluate the nature of the autoimmune reactions (i.e. risks) associated with the hepatitis B vaccine and to determine if individuals who will have these adverse reactions can be identified in advance of receiving the vaccine". There are critical questions that must be addressed to establish the risk/benefit of the current hepatitis B vaccines in the United States. These questions are particularly important in view of recent mandates to vaccinate all children including newborn infants." You may read this grant proposal at http://webpages.netlink.co.nz/~ias/dunbar.htm Many groups have called for a moratorium on hepatitis B vaccination until some of these questions can be answered adequately. The NVIC reported "Newborn babies are dying shortly after their shots and their deaths are being written off as sudden infant death syndrome. Parents should have the right to give their informed consent to vaccination and Congress should give emergency, priority funding to independent scientists, who can take an unbiased look at this vaccine, instead of leaving the search for truth in the hands of government officials who have already decided to force every child to get the vaccine". We agree completely. The NVIC can be contacted at http://www.909shot.com for further information. In Dr. Coulter's book, "Vaccination, Social Violence, and Criminality" the thesis is developed that the "sociopathic personality" which has emerged on a mass scale in recent decades; and which is responsible for a disproportionate amount of crime and violence;is causally linked to the childhood vaccination program. Vaccination frequently causes encephalitis and neuropathy that in turn leads to these post-encephalitic states and conditions. In his book, Dr. Coulter presents a time line of increase in developmental disability related to vaccine introduction that is indeed frightening. Dr. Coulter believes about 20% of our children are suffering from this neurological vaccine damage. We believe some of these vaccine experts should be on the President's Youth Violence task force. Our own school district's confidential health statistics show at least 20% of our children (K-3) have significant neurological damage and/or chronic illness. The last three years have shown an acceleration in the numbers of children who are entering our schools with these "developmental disorders". (Could these be the same infants who received the first trial doses of hepatitis B as only a few hour-old newborns?) As school nurses, working with these damaged children on a daily basis, we pray this is not true. If it is, the ramification to this generation of children is unthinkable! Should we not pause, call for a moratorium on these poorly tested, rapidly approved vaccines, and allow independent American physicians and researchers to study them before blindly injecting an experimental vaccine into an entire generation? (We have found the only ones declaring the vaccine's safety are the ones who are making millions of dollars from its sales, whose employment depends on it or the ones being funded by the drug companies vast number of grants and fundings. The independent researchers seem to be coming up with an entirely different report.) Vaccine producers have nothing to lose since our U.S. Congress has made them immune from responsibility or liability for injuries caused from their vaccines. The push is on for them to create more and more vaccines. There are huge amounts of money being made by these people who no longer worry about the consequences of their inadequate clinical trials. The United States government has had to pay out nearly a billion dollars in damages to families who can prove their children have been damaged or killed by vaccines, and there are thousands more cases pending. I just read that there are so many vaccine damage claims that Secretary Shalala changed the rules to try to limit adverse reaction claims. Could this be true? If so, shame on our government. We believe, as medical professionals, that we are doing a great disservice to our country by forcing government mandated vaccines on all children. Please research this and we pray you have the courage to speak out and tell the nation what you find. Sincerely, Patti White, RN School Health Services Coordinator Warrensburg R-VI School District Warrensburg Mo 64093 and Missouri Central District School Nurse Association rpwhi...@iland.net  Signature*************************************************************** Karin Schumacher Vaccine Information & Awareness (VIA) 12799 La Tortola San Diego, CA 92129 619-484-3197 (phone/voicemail) 619-484-1187 (fax) v...@access1.net (email) http://www.909shot.com (NVIC website) http://www.access1.net/via (VIA website) *************************************************************** We Must Have The Freedom To Choose & Respect Everyone's Choice >> provided evidence that there are no causes for concern, but then others >> like Jan have given evidence that there *IS* cause for concern. To me, [quoted text clipped - 7 lines] > Sure some kids get to die, or have complications, but this number is far > far smaller than results from non-vaccination. You know, if you can't answer my question, then just don't post. You're opinions are worthless to me. It's of no concern to me that you think my wanting to get to know my child before getting it injected with a foreign substance "doesn't come across well." To me, it doesn't come come across well that you would question such a simple idea. If you can't provide a valid answer to the question, then just keep quiet. Max. > > I've always been curious to know... could you explain to me why it is > > felt necessary to give the HepB vaccine on the day of birth? Why the [quoted text clipped - 14 lines] > Sure some kids get to die, or have complications, but this number is > far far smaller than results from non-vaccination. >> I've always been curious to know... could you explain to me why it is >> felt necessary to give the HepB vaccine on the day of birth? Why the >> rush? Shouldn't parents be given a chance to get to know their babies' >> personalities before giving such a questionable shot? Sure you've > > I'm not sure what you're getting at here but it doesn't come across well. They give it at birth! Just incase your child is going to be an IV drug user, or sex fiend. http://www.whale.to/vaccine/point.html > In case you haven't been paying attention the risk/benefit analysis falls > on the side of vaccination. wishful thinking, called a rationalization http://www.whale.to/vaccine/rationalization_h.html > Sure some kids get to die, or have complications, but this number is far > far smaller than results from non-vaccination. You wish! AT LEAST 26 families claim their children died as a result of the controversial measles, mumps and rubella jab, the Sunday Express can reveal. http://www.whale.to/v/mmr101.html And measles is safe in well managed kids. "Under normal conditions, healthy children do not die from or become disabled from the complications of measles and if they do, questions should be asked about their management." ---Jayne Donegan MB http://www.whale.to/m/quotes19.html >AT LEAST 26 families claim their children died as a result of the >controversial measles, mumps and rubella jab, the Sunday Express can reveal. >http://www.whale.to/v/mmr101.html That doesn't mean their claim is accurate. >And measles is safe in well managed kids. So any kid who dies or suffers permanent disability can just be dismissed as "mismanaged" and the the anti-vaxers can continue to keep their heads comfortably submerged in the sand. -- David Wright :: alphabeta at prodigy.net These are my opinions only, but they're almost always correct. "If you can't say something nice, then sit next to me." -- Alice Roosevelt Longworth > I've always been curious to know... could you explain to me why it is > felt necessary to give the HepB vaccine on the day of birth? Because there is an extremely high risk of mother-to-child transmission, child-to-child transmission, and children represent the primary reservoir for HepB. Not to mention that HepB is far more deadlier in infants then in older persons. And if you look at the schedule you'll see that if a mothers HepB status is known to be negative then vaccination can be delayed, although this delay is strongly recommended against: http://www.keepkidshealthy.com/welcome/immunizations/2006_immunization_schedule.html > Why the > rush? Shouldn't parents be given a chance to get to know their babies' [quoted text clipped - 4 lines] > for concern unless it specifically and fully addresses the reasons that > are of concern. It's a matter of risk management. Nothing we do, including being born, is without risk. And like everything else in life, vaccination does carry risks. But the risks far outweigh the risk of not being vaccination. In the case of HepB it is particularly damaging to children - whereas 1-2% of adults infected with HepB develop chronic and deadly disease, 30-50% of infected infants will develop chronic and deadly disease. We put our kids into child seats in the car, put sunscreen onto them to protect them from UV, make them wear helmets when they ride a bike, all in the name of risk management. Vaccination is the same thing, a way to protect our children. And like everything else we do to protect our kids, it is not perfect, but it is better then doing nothing at all. Bryan I'm sorry but I disagree with this form of vaccination at this age. I am not sure about it being an everyday thing done to people except those who might be at risk. My son got a major cocktail of who knows what in the army. I fear what all of it will do to him in the future esp. since he already is injured through his service to this country. UM MOM Susan >> I've always been curious to know... could you explain to me why it is >> felt necessary to give the HepB vaccine on the day of birth? [quoted text clipped - 33 lines] > > Bryan Hep B #1 in the hospital (first day of life) 2 Months - Hep B, Hib, DTaP, IPV, PCV 4 months - Hib, DTaP, IPV, PCV 6 months - Hep B, Hib, DTaP, IPV, PCV That's 5 types of shots, 15 actual shots, and 21 immunizations if you count the D, T, and acellular P separately. > I'm sorry but I disagree with this form of vaccination at this age. I am > not sure about it being an everyday thing done to people except those who [quoted text clipped - 39 lines] >> >> Bryan > Hep B #1 in the hospital (first day of life) > 2 Months - Hep B, Hib, DTaP, IPV, PCV > 4 months - Hib, DTaP, IPV, PCV > 6 months - Hep B, Hib, DTaP, IPV, PCV > That's 5 types of shots, 15 actual shots, and 21 immunizations if you > count the D, T, and acellular P separately. Wonderful. All that protection so early in life. >> I'm sorry but I disagree with this form of vaccination at this age. I am >> not sure about it being an everyday thing done to people except those who [quoted text clipped - 39 lines] >>> >>> Bryan >> Hep B #1 in the hospital (first day of life) >> 2 Months - Hep B, Hib, DTaP, IPV, PCV [quoted text clipped - 4 lines] > > Wonderful. All that protection so early in life. http://www.909shot.com/Kids/terry.htm http://www.909shot.com/Kids/richie.htm http://www.909shot.com/Kids/nicky.htm http://www.909shot.com/Kids/anna.htm http://www.healing-arts.org/children/vaccines/vaccines-database.htm#d... >>> I'm sorry but I disagree with this form of vaccination at this age. I >>> am not sure about it being an everyday thing done to people except those [quoted text clipped - 43 lines] >>>> >>>> Bryan >>> Hep B #1 in the hospital (first day of life) >>> 2 Months - Hep B, Hib, DTaP, IPV, PCV [quoted text clipped - 3 lines] >>> count the D, T, and acellular P separately. >> Wonderful. All that protection so early in life. Anti-vac websites deleted. Jan added nothing worth quoting. >>>> I'm sorry but I disagree with this form of vaccination at this age. I >>>> am not sure about it being an everyday thing done to people except those [quoted text clipped - 41 lines] >>>>> >>>>> Bryan >>>> Hep B #1 in the hospital (first day of life) >>>> 2 Months - Hep B, Hib, DTaP, IPV, PCV [quoted text clipped - 7 lines] > > Jan added nothing worth quoting. Sad.. that Mark believes these children lives are worthless. Wonder why he hates children so much? Restored the truth: http://www.909shot.com/Kids/terry.htm http://www.909shot.com/Kids/richie.htm http://www.909shot.com/Kids/nicky.htm http://www.909shot.com/Kids/anna.htm http://www.healing-arts.org/children/vaccines/vaccines-database.htm#d... >>>>> I'm sorry but I disagree with this form of vaccination at this age. I >>>>> am not sure about it being an everyday thing done to people except [quoted text clipped - 45 lines] >>>>>> >>>>>> Bryan >>>>> Hep B #1 in the hospital (first day of life) >>>>> 2 Months - Hep B, Hib, DTaP, IPV, PCV [quoted text clipped - 8 lines] > > Sad.. that Mark believes these children lives are worthless. Wrong. You posted from anti-vac liar websites, which are, ipso facto, not worth quoting. > Wonder why he hates children so much? INCORRECT! Unlike the anti-vac liars, I love LIVE & HEALTHY children. >> I've always been curious to know... could you explain to me why it is >> felt necessary to give the HepB vaccine on the day of birth? [quoted text clipped - 33 lines] > > Bryan Ohh, looky what the AAPS has taken down from Canada, since 2003! I still have it..because *I* posted it! http://64.41.99.118/vran/vaccines/hepatitis/vaccine_hep.htm VACCINES HEPATITIS-B HEP-B VACCINE, an UNJUSTIFIED HEALTH HAZARD Across Canada each year, thousands of school children are lined up and injected with hepatitis B vaccine. Parents are not adequately informed of the risks associated with the vaccine nor are they told that children in Canada have an extremely low risk of contracting the disease. Hepatitis B is not a common childhood disease. The risk according to recent statistics from Health Canada is minute, with only 25 cases reported in 1998 in children under the age of 14 in the entire country, yet thousands of children every year are exposed to the hazards of the vaccine. Parents are not told that hepatitis B vaccine is genetically engineered, that it contains thimerosal a known neurotoxin, and that no long term follow up for adverse reactions has been done. Pre-marketing clinical trials lasted only 4-5 days, not long enough to determine automimmune reactions that can take weeks and months to emerge. According to vaccine researcher, Dr. Bonnie Dunbar, "The pathologies that are common to hepatitis B virus infections are the same types of symptoms that are associated with both the plasma derived (old vaccine) and the new yeast derived recombinant hepatitis B vaccine. These include rheumatoid arthritis type symptoms, optic neuritis, multiples sclerosis like symptoms, demyelinating disorders and a variety of vascular disorders and chronic fatigue syndrome." Dr. Dunbar reports that "we re finding there are 3 basic categories of adverse reactions. When you look at the published reports in the literature we have a majority of neurological type of symptoms, rheumatic/rheumatology, autoimmune types of symptoms and a variety of others vascular, etc." In a resolution voting against mandatory childhood vaccines, members of the Association of American Physicians and Surgeons stated that "children under the age of 14 are three times more likely to suffer adverse effects -- including death -- following the hepatitis B vaccine than to catch the disease itself." While Canadian statistics are sparse on vaccine associated adverse events, the VAERS adverse events reporting system in the United States offers the following statistics. To be sure, a similar trend would be expected in Canada. http://www.aapsonline.org/aaps/ Overall, VAERS has received a total of 17,497 reports of adverse reactions to the hepatitis B vaccine, reactions that occurred after people received the vaccine alone, rather than in combination with other vaccines, during the period between July 1, 1990 and October 21, 1998. Moreover, fully 5,983 of these reports chronicled such serious events as hospitalizations, while 146 of them told of deaths. VAERS, furthermore, is a passive system, not a mandatory one. This suggests that only a fraction of adverse events are actually reported, a fraction estimated by FDA officials to be as low as 1% to 10%. http://www.biospace.com/articles/111199.cfm Until recently the vaccine was given in a three dose schedule - the first dose usually started in the fall at the begining of the new school term, a second injected dose about a month later, and the third dose approximately 6 months later. In July 2000, The National Advisory Committee on Immunization (NACI) announced a revised schedule under the heading "The Statement on Alternate Adolescent Schedule for Hepatitis B Vaccine", published in the Canada Communicable Diseases Report - Vol. 26 (ACS-5), July 1, 2000. This brief report announces that children age 11-15 will have available a two dose schedule to be given in the school setting, and identifies the vaccine as Merck Frosst's Recombivax HB, but omits pertinent product information and does not disclose details of how the new 2 dose hepatitis B vaccine differs from the old 3 dose vaccine. The NACI statement can be viewed online at: http://www.hc-sc.gc.ca/hpb/lcdc/publicat/ccdr/00vol26/26sup/acs5.html The timeline of the hepatitis B vaccine program varies from province to province. Some provinces start injecting children in Grade 3, others start in grade 4, 5, 6, or 7, and high schools offer catch up campaigns for students who missed their shots in elementary school. New Brunswick, and the North West Territories routinely inject newborn infants within hours of birth with hepatitis B vaccine, while also offering it with the early infant shots starting at two months. Prince Edward Island includes it in the infant shots and also offers it in schools. British Columbia recently also has added hepatitis B vaccine to its routine infant vaccination program, starting at two months. According to the Canadian Immunization Guide - Fifth edition (1998), " HBV infection is usually associated with exposure to blood or infectious bodily fluids. Common means of transmission include heterosexual and homosexual contact, injection drug use, and perinatal transmission (mother to infant). The risk of transfusion-related hepatitis B is extremely low because of routine HBsAg screening of donated blood and rejecting of donors at risk of infection. Infections also occur in settings of close personal contact through unrecognized contact with infective fluids." People at high risk for getting hepatitis B disease are intravenous drug users who share contaminated needles, prostitutes, prisoners, sexually promiscuous persons and babies born to infected mothers. Canada offers prenatal blood screening (which includes testing for hepatitis B infection) to all pregnant women, and in rare cases of maternal infection, newborn infants are immeditely treated with hepatitis B immune globulin (HBIG), which offers immediate short term passive immunity. Immune globulin is prepared from pooled human plasma from selected donors wth high level of anti-HBs who are seronegative for bloodborne infections. This screening and treatment insures that vulnerable, at risk infants are protected from acquiring hepatitis B and effectively reduces their risk of becoming lifelong carriers of the disease. The majority of adults, and older children who might rarely contract the disease usually recover, and develop lifelong immunity. Only a small percentage of people who contract hepatitis B go on to become carriers of the disease and/or develop degenerative liver disease. Health Canada reports "an encouraging picture of declining incidence of HBV infection in Canada in recent years. The reasons for this apparent decline remain speculative. A high-risk group approach to the use of hepatitis B vaccine has been in place in Canada since 1982 (3) and prenatal screening, at first targeted at high-risk pregnant women and later at all pregnant women, has also been in place since 1982..........A downward trend for the incidence of HBV in the early 1990s has also been reported in the United States and has been partly ascribed to declining transmission among injection drug users, possibly as a result of safer needle-using" http://www.hc-sc.gc.ca/hpb/lcdc/publicat/ccdr/97vol23/dr2307eb.html >>> I've always been curious to know... could you explain to me why it is >>> felt necessary to give the HepB vaccine on the day of birth? [quoted text clipped - 35 lines] > > Ohh, looky what the AAPS has taken down from Canada, since 2003! The anti-vac AAPS which is fully explained here: http://tinyurl.com/pxsq9 Surely not a reputable organization. > I still have it..because *I* posted it! > [quoted text clipped - 154 lines] > > http://www.hc-sc.gc.ca/hpb/lcdc/publicat/ccdr/97vol23/dr2307eb.html "Mark Probert" <snip> >>>> I've always been curious to know... could you explain to me why it is >>>> felt necessary to give the HepB vaccine on the day of birth? [quoted text clipped - 36 lines] >> >> Ohh, looky what the AAPS has taken down from Canada, since 2003! >> I still have it..because *I* posted it! >> [quoted text clipped - 178 lines] >> >> http://www.hc-sc.gc.ca/hpb/lcdc/publicat/ccdr/97vol23/dr2307eb.html > "Mark Probert" > [quoted text clipped - 36 lines] >>>> Bryan >>> Ohh, looky what the AAPS has taken down from Canada, since 2003! With Thunderbird, it is SOOOOOO easy to find Jan's snips. The anti-vac AAPS which is fully explained here: http://tinyurl.com/pxsq9 Surely not a reputable organization. >> "Mark Probert" >> [quoted text clipped - 41 lines] >>>>> >>>>> Bryan Ohh, looky what the AAPS has taken down from Canada, since 2003! [Mark does not want it to be shown, too bad] Ohh, looky what the AAPS has taken down from Canada, since 2003! I still have it..because *I* posted it! http://64.41.99.118/vran/vaccines/hepatitis/vaccine_hep.htm VACCINES HEPATITIS-B HEP-B VACCINE, an UNJUSTIFIED HEALTH HAZARD Across Canada each year, thousands of school children are lined up and injected with hepatitis B vaccine. Parents are not adequately informed of the risks associated with the vaccine nor are they told that children in Canada have an extremely low risk of contracting the disease. Hepatitis B is not a common childhood disease. The risk according to recent statistics from Health Canada is minute, with only 25 cases reported in 1998 in children under the age of 14 in the entire country, yet thousands of children every year are exposed to the hazards of the vaccine. Parents are not told that hepatitis B vaccine is genetically engineered, that it contains thimerosal a known neurotoxin, and that no long term follow up for adverse reactions has been done. Pre-marketing clinical trials lasted only 4-5 days, not long enough to determine automimmune reactions that can take weeks and months to emerge. According to vaccine researcher, Dr. Bonnie Dunbar, "The pathologies that are common to hepatitis B virus infections are the same types of symptoms that are associated with both the plasma derived (old vaccine) and the new yeast derived recombinant hepatitis B vaccine. These include rheumatoid arthritis type symptoms, optic neuritis, multiples sclerosis like symptoms, demyelinating disorders and a variety of vascular disorders and chronic fatigue syndrome." Dr. Dunbar reports that "we re finding there are 3 basic categories of adverse reactions. When you look at the published reports in the literature we have a majority of neurological type of symptoms, rheumatic/rheumatology, autoimmune types of symptoms and a variety of others vascular, etc." In a resolution voting against mandatory childhood vaccines, members of the Association of American Physicians and Surgeons stated that "children under the age of 14 are three times more likely to suffer adverse effects -- including death -- following the hepatitis B vaccine than to catch the disease itself." While Canadian statistics are sparse on vaccine associated adverse events, the VAERS adverse events reporting system in the United States offers the following statistics. To be sure, a similar trend would be expected in Canada. http://www.aapsonline.org/aaps/ Overall, VAERS has received a total of 17,497 reports of adverse reactions to the hepatitis B vaccine, reactions that occurred after people received the vaccine alone, rather than in combination with other vaccines, during the period between July 1, 1990 and October 21, 1998. Moreover, fully 5,983 of these reports chronicled such serious events as hospitalizations, while 146 of them told of deaths. VAERS, furthermore, is a passive system, not a mandatory one. This suggests that only a fraction of adverse events are actually reported, a fraction estimated by FDA officials to be as low as 1% to 10%. http://www.biospace.com/articles/111199.cfm Until recently the vaccine was given in a three dose schedule - the first dose usually started in the fall at the begining of the new school term, a second injected dose about a month later, and the third dose approximately 6 months later. In July 2000, The National Advisory Committee on Immunization (NACI) announced a revised schedule under the heading "The Statement on Alternate Adolescent Schedule for Hepatitis B Vaccine", published in the Canada Communicable Diseases Report - Vol. 26 (ACS-5), July 1, 2000. This brief report announces that children age 11-15 will have available a two dose schedule to be given in the school setting, and identifies the vaccine as Merck Frosst's Recombivax HB, but omits pertinent product information and does not disclose details of how the new 2 dose hepatitis B vaccine differs from the old 3 dose vaccine. The NACI statement can be viewed online at: http://www.hc-sc.gc.ca/hpb/lcdc/publicat/ccdr/00vol26/26sup/acs5.html The timeline of the hepatitis B vaccine program varies from province to province. Some provinces start injecting children in Grade 3, others start in grade 4, 5, 6, or 7, and high schools offer catch up campaigns for students who missed their shots in elementary school. New Brunswick, and the North West Territories routinely inject newborn infants within hours of birth with hepatitis B vaccine, while also offering it with the early infant shots starting at two months. Prince Edward Island includes it in the infant shots and also offers it in schools. British Columbia recently also has added hepatitis B vaccine to its routine infant vaccination program, starting at two months. According to the Canadian Immunization Guide - Fifth edition (1998), " HBV infection is usually associated with exposure to blood or infectious bodily fluids. Common means of transmission include heterosexual and homosexual contact, injection drug use, and perinatal transmission (mother to infant). The risk of transfusion-related hepatitis B is extremely low because of routine HBsAg screening of donated blood and rejecting of donors at risk of infection. Infections also occur in settings of close personal contact through unrecognized contact with infective fluids." People at high risk for getting hepatitis B disease are intravenous drug users who share contaminated needles, prostitutes, prisoners, sexually promiscuous persons and babies born to infected mothers. Canada offers prenatal blood screening (which includes testing for hepatitis B infection) to all pregnant women, and in rare cases of maternal infection, newborn infants are immeditely treated with hepatitis B immune globulin (HBIG), which offers immediate short term passive immunity. Immune globulin is prepared from pooled human plasma from selected donors wth high level of anti-HBs who are seronegative for bloodborne infections. This screening and treatment insures that vulnerable, at risk infants are protected from acquiring hepatitis B and effectively reduces their risk of becoming lifelong carriers of the disease. The majority of adults, and older children who might rarely contract the disease usually recover, and develop lifelong immunity. Only a small percentage of people who contract hepatitis B go on to become carriers of the disease and/or develop degenerative liver disease. Health Canada reports "an encouraging picture of declining incidence of HBV infection in Canada in recent years. The reasons for this apparent decline remain speculative. A high-risk group approach to the use of hepatitis B vaccine has been in place in Canada since 1982 (3) and prenatal screening, at first targeted at high-risk pregnant women and later at all pregnant women, has also been in place since 1982..........A downward trend for the incidence of HBV in the early 1990s has also been reported in the United States and has been partly ascribed to declining transmission among injection drug users, possibly as a result of safer needle-using" http://www.hc-sc.gc.ca/hpb/lcdc/publicat/ccdr/97vol23/dr2307eb.html >>> "Mark Probert" >>> [quoted text clipped - 49 lines] > > I still have it..because *I* posted it! Yes, you are incurable. The anti-vac AAPS which is fully explained here: http://tinyurl.com/pxsq9 Surely not a reputable organization. >I notice you were very selective in the papers you posted - here's the >other side of the story. The side that in your dishonesty, you chose not >to present: lol... Right backatcha there, Byan. Once, again your insult is noted...as usual they always flow, when the *truth* is posted. I presented the *TRUTH*. Here is more. Came from guess where? http://movies.commons.ucalgary.ca/mercury/ Umm Jan, that video is talking about metallic mercury - as in pure mercury. Pure mercury is not in vaccines; rather it is a salt containing mercury. So the two aren't comparable, apples and oranges and all that. Table salt is a perfect example of this. Table salt is composed of sodium metal linked to chlorine. Chlorine is an extremely toxic gas - so toxic it was used as a chemical weapon in WWI, and many times more toxic then mercury. Likewise, sodium is highly dangerous - pure sodium will instantly react with nearly anything, often with explosive results. But when the two come together you get an inert substance, which is much less toxic then the original products. But by your logic table salt should be as toxic as it's constituent elements. We both know that is not true. The mercury salts used in vaccines are much the same - pure mercury is one of the more toxic things people encounter, particularly when inhaled. But many of mercury's salts are benign, especially when compared to the metal itself. The knife cut both ways too - some mercury salts (methyl mercury for example) are actually more toxic then mercury alone. As they say, nothing in life is simple. But hey, you're apparent inability to tell the difference between pure metals and there salts in duly noted, and also provides interesting insite into you apparent inability to understand other basic scientific concepts. Bryan >Umm Jan, that video is talking about metallic mercury - as in pure >mercury. Pure mercury is not in vaccines; rather it is a salt [quoted text clipped - 22 lines] > >Bryan You're wasting your time, Bryan. The sodium-chlorine-table salt thing has been pointed out to Jan many times and she calls it a diversion. As for the toxicity of mercury compounds, she loves to cite ex-professor Boyd Haley (who now sells chelation full time) as an expert. Haley told me that the proportion of molecular weight coming from an atom of mercury in the compound is relevant to the chemistry of the compound. He also said that as there are no listed safety issues with ethylmercury it is appropriate to use the EPA guidelines for methylmercury when talking about the ethyl- compound as they are basically the same thing. Did I mention that he is an ex-professor of chemistry? SignaturePeter Bowditch aa #2243 The Millenium Project http://www.ratbags.com/rsoles Australian Council Against Health Fraud http://www.acahf.org.au Australian Skeptics http://www.skeptics.com.au To email me use my first name only at ratbags.com ...> > You're wasting your time, Bryan. The sodium-chlorine-table salt thing > has been pointed out to Jan many times and she calls it a diversion. [quoted text clipped - 8 lines] > > Did I mention that he is an ex-professor of chemistry? Oh.. Did he leave the university voluntarily? Or was he asked to leave? If he left voluntarily, it might mean that scamming desperate parents is more lucrative than teaching and research. >...> >> You're wasting your time, Bryan. The sodium-chlorine-table salt thing [quoted text clipped - 16 lines] >If he left voluntarily, it might mean that scamming desperate parents is >more lucrative than teaching and research. I may have been misinformed, as the University of Kentucky web site still lists him as a professor (although he no longer appears to be chairman of the department). His original quackery laboratory gives the campus of UK as its address, but I can't reach his other business at the moment because its web site is down. (Cue Jan to say that this is because the orthodoxy have shut him down.) http://www.testfoundation.org - Motto: Absence of proof is not proof of absence. He doesn't just scam parents. He offers a test (for $500) which can tell young people if they are going to get ALS when they are 70. As I said when I first heard about this: "I see that he is charging $500 for an unapproved test for Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's Disease). All the published research about the test and its underlying theory was done by, wait for it, don't get impatient, Dr Boyd Haley. If he follows the pattern of fraud used in the Roy Smith(*) case, then he will find the marker for ALS and then tell whoever has been tested that they need to have some very expensive chelation to fix the problem. "Testing young people for ALS and then treating them is a much better scam than curing cancer or diabetes. You do the test, produce the "positive" results and give the treatment. ALS is quite rare and doesn't show up until the victim is getting on in years, so if the person never gets it (like most of the population) they will thank Haley and not begrudge him the money he took. If they do happen to get ALS, Haley will be long gone with the money, and, even if he is still around, he can claim that the treatment is not perfect. In fact, it's a perfect scam. "I am offering a test for prostate cancer. It costs $450 and requires a urine sample. It is such a sensitive test that it is only useful on men less than twenty years old, because after that the testing equipment gets overloaded. The treatment costs $10,000 and comes with a five-year guarantee. If you don't require surgery by the time you are forty years old then it is obvious that the treatment worked. I am also working on a test for presbyopia, to be given to 12-year-olds. The test will cost about $300 and the treatment for indolent asymptomatic presbyopia will cost $1,000. If you don't need reading glasses by the age of 30 the treatment worked. "Well, I would be doing those things if I didn't have a conscience". http://www.ratbags.com/rsoles/comment/haley.htm (*) You can read about the disgusting fraud perpetrated on the dying Roy Smith at http://www.ratbags.com/rsoles/comment/altmedicine.htm SignaturePeter Bowditch aa #2243 The Millenium Project http://www.ratbags.com/rsoles Australian Council Against Health Fraud http://www.acahf.org.au Australian Skeptics http://www.skeptics.com.au To email me use my first name only at ratbags.com > You're wasting your time, Bryan. Not so. I have no illusions; I will never get Jan et al to switch teams. I'm writing for the benefit of others who may be reading these exchanges. Hopefully they'll see both sides of the story, rather then the rather polarized side that Jan likes to present... > Haley told me that the proportion of molecular weight coming > from an atom of mercury in the compound is relevant to the chemistry > of the compound. That's a pretty simplistic description. Electron availability is what tends to confer toxicity to heavy metals. So any mercury compound where the mercury electrons are bound/coordinated by the remainder of the molecule will be less toxic then compounds which leave these electrons free. > He also said that as there are no listed safety > issues with ethylmercury it is appropriate to use the EPA guidelines > for methylmercury when talking about the ethyl- compound as they are > basically the same thing. Wow, that's a pretty big claim, especially given the huge known differences in toxicity and bioaccumulation: http://en.wikipedia.org/wiki/Ethylmercury#_note-1 > Did I mention that he is an ex-professor of chemistry? With medical background? Bryan >> You're wasting your time, Bryan. > [quoted text clipped - 19 lines] > > Wow, that's a pretty big claim, And a BIG lie. especially given the huge known > differences in toxicity and bioaccumulation: > [quoted text clipped - 5 lines] > > Bryan Never mind, Peter..he is jealous. BOYD E. HALEY, Ph.D. Born 22-09-40 Greensburg, Indiana ADDRESS: Advanced Science Technology Commercialization Center, ASTeCC Room A057 University of Kentucky Lexington, KY 40506-0286 Laboratory: Telephone; (606) 257-2300 ext 246 FAX; (606) 257-3040 Chemistry Office: Telephone; (606) 257-7082 EDUCATION: Institution Year Degree/Area Franklin College 1963 B.A./Chemistry-Physics University of Idaho 1967 M.S./Organic Chemistry Washington State University 1971 Ph.D./Chemistry-Biochemistry Yale University Medical Center 1971-74 Postdoctoral Fellow RESEARCH AND PROFESSIONAL EXPERIENCE: 1963-1964 Research Scholar, Food and Drug Administration. 1964-1966 U.S. Army Medic 1966-1967 Graduate Student, University of Idaho 1967-1971 Graduate Student, Washington State University 1971-1974 Postdoctoral Scholar, Yale University 1974-1979 Assistant Professor, Department of Biochemistry, University of Wyoming, Laramie, WY 1979-1981 Associate Professor, Department of Biochemistry, University of Wyoming, Laramie, WY 1981-1985 Professor, Department of Biochemistry, University of Wyoming, Laramie, WY 1985-1997 Professor of Medicinal Chemistry, College of Pharmacy, University of Kentucky, with joint appointments in Biochemistry & Chemistry 1997-present Chairman & Professor, Department of Chemistry with joint appointment in College of Pharmacy PROFESSIONAL ORGANIZATIONS, SOCIETIES, HONORS AND RESPONSIBILITIES 1959 President's Scholarship, Franklin College, Indiana 1962 Chi Beta Phi, Franklin College 1962 James M. Sprague Award - $400 award to outstanding undergraduate junior majoring in science. 1963 Kennedy Scholar, Food and Drug Administration, Washington, D.C. 1970 Sigma Xi 1975 Dreyfus Foundation Visiting Researcher, Enzyme Institute University of Wisconsin 1977 American Society of Biological Chemists 1981 Biophysical Society 1981 Served on NIH Physiological Chemistry Study Section 1981 Research was presented as a "highlight" in NIH report on "Cellular and Molecular Basis of Disease Program" 1984 "TOP" Professor Award, University of Wyoming 1982 Served on NIH Physiological Chemistry Study Section 1983 Served on NIH Physiological Chemistry Study Section 1985 Permanent member NIH Biomedical Sciences, Study Section 1991 Honorary Doctorate in Arts & Sciences, Franklin College 1992 Society for Neuroscience GRANT SUPPORT 1975 - 1978 National Institutes of Health, "Application of Photoaffinity Nucleotide Analogs", $82,000, Prinicipal Investigator 1975 Research Coordination Committee, University of Wyoming $1,800 1978 - 1981 National Institutes of Health, "Application of Photoaffinity Nucleotide Analogs", $183,696, Prinicipal Investigator 1978 - 1981 Eleanor Roosevelt Cancer Institute Grant, $11,400 1979 - 1983 PHS Research Career Development Award, $185,000 1981 - 1986 National Institutes of Health, "Application of Photoaffinity Nucleotide Analogs", $434,000, Prinicipal Investigator 1982 ASBC Travel Award to attend 12th IVB Congress, Perth, Australia 1983 - 1984 National Science Foundation, "Melatonin Photoaffinity Probe", $84,000, Co-Principal Investigator 1983 - 1985 National Institutes of Health, "Epididymal Sperm Nucleotide Binding proteins", $190,000, Co-Principal Investigator 1985 - 1988 U.S. Army Mycotoxin Photoprobes, $390,000, Co-Principal Investigator 1986 - 1989 NIH, "Forskolin Photoaffinity Probes", $170,000, Co-Principal Investigator 1986 - 1991 NIH, "Application of Photoaffinity Nucleotide Analogs" $781,661, Principal Investigator 1989 - 1994 NIH, "Nucleotide-Tubulin Interactions in Alzheimer's Disease", $405,259, Co-Prinicipal Investigator 1990 - 1996 Lexington Clinic Foundation For Medical Education and Research, "Inhibition of Neoplastic Cell Proliferation Through Utilization of Photoactive DNA & RNA Synthesis, $100,000, P.I. 1990 - 1993 Eli Lilly, "Development of a Diagnostic Test for Alzheimer's Disease, $378,000, P.I. 1995 - 1997 Wallace Research Foundation, "Development of Diagnostic Tests Using Nucleotide Photoaffinity Probes". $109,000 for two years. 1997-1998 Wallace Research Foundation, "Development of Diagnostic Tests Using Nucleotide Photoaffinity Probes". $74,344. 1997-2000 NIH, "Application of Photoaffinity Nucleotide Analogs", $378,081, P.I. 1997-1998 Isostent, Inc. "Photoattachment of 32P to angioplastic ballon cathers" $52,000. Pending NIH, "Identification of CSF proteins Related to ALS" NIH, "Photomodification of Antibodies for Diagnostic and Therapeutic Applications". TEACHING EXPERIENCE Introductory Comparative Biochemistry General Biochemistry Problems and Topics in Biochemistry Mercury Toxicity: Chemistry and Biochemistry Involved Advanced Problems and Topics in Biochemistry Nucleic Acids and Protein Biosynthesis Nucleotides in Regulation of Biological Phenomena Bioenergetics Medicinal Chemistry Natural Products and Bio-organics Graduate level Biochemistry, Protein Chemistry INVITED LECTURES: 1975 - Sloan Kettering Memorial Cancer Institute, New York thru Colorado State University (3) 1979 Albert Einstein University, New York Hoffman-LaRoche Research Institute, Nutley, New Jersey University of Colorado Medical School Denver (3) University of Colorado, Boulder (2) Yale University Medical School (2) The Salk Institute, San Diego University of California, Davis Stanford University Medical School University of California, San Diego University of Washington, Seattle Washington State University Kansas State University 1979 Symposium Speaker, ASBC Meeting, Dallas, Texas 1979 Symposium Speaker, New York Academy of Sciences Meeting, New York Department of Molecular Biology, National Jewish Hospital, Denver University of California, Riverside Workshop Speaker, ICN-UCLA Conference on Adenylyl Cyclase 1982 Symposium Speaker, 1982 FASEB Meeting, New Orleans 1982 Guest Lecturer and Scientist, German Cancer Research Center, Institute of Cell and Tumor Biology, Heidelberg, West Germany, May 1982 Centre National De La Recherche Scientifique, Laboratoire D'Enzymologie, Gif Sur Yvette, France, June 1982 Workshop Speaker, ASBC Meeting in New Orleans (Photoprobe utilization, sponsored by Schwarz-Mann) 1982 Symposium Speaker, Society for the Study of Reproduction, Madison Wisconsin, August 1982 Department of Biochemistry, University of Wisconsin, November 1982 Department of Chemistry, New Mexico State University, November 1982 Department of Chemistry, University of Colorado, December 1983 Institute of Infectious Diseases, U.S. Army Medical Research Institute, Ft. Detrick, Michigan, January 1983 Department of Biochemistry and Biophysics, Oregon State University 1983 Department of Biochemistry, Texas Health Science Center, San Antonio, TX 1983 Department of Biochemistry, University of Mississippi Medical Center 1984 Department of Biochemistry, University of Kentucky, Lexington, KY 1985 Department of Physiology and Biophysics, Northwestern University Medical School, Chicago, Illinois 1985 Department of Chemistry, University of Southern California, Los Angeles, California 1985 Department of Physiology, University of Illionis at Chicago, Chicago, Illinois 1985 Department of Biochemistry, Ohio State University, Columbus, Ohio 1985 Department of Physiology, Yale University Medical School, New Haven, Connecticut 1986 Department of Biochemistry, Case Western University, School of Medicine, Cleveland, Ohio 1986 Department of Biochemistry, Indiana University, School of Medicine, Indianapolis, Indiana 1986 Department of Biochemistry, Washington University, School of Medicine, St. Louis, Missouri 1987 Division Fermentation Products Research Division, Eli Lilly Research Laboratories, Indianapolis, Indiana 1987 Department of Chemistry, University of South Florida, Tampa, Florida 1987 Department of Molecular Biology and Biochemistry, University of Wyoming, Laramie, Wyoming 1988 Worcester Foundation, Shrewsbury, Massachusetts 1988 Department of Biochemistry, University of Colorado, Denver, Colorado 1988 Department of Biochemistry, University of Delaware, Newark, Delaware 1989 University of California at San Diego 1989 University of California at Los Angeles 1989 Texas College of Osteopathic Medicine, Fort Worth, Texas 1990 Wright State University, Dayton, Ohio 1990 Athena Neurosciences, S. San Francisco, California 1990 Eli Lilly & Co., Indianapolis, Indiana 1990 Connaught Laboratories, Toronto, Canada 1990 University of East Carolina Medical School, Greenville, North Carolina 1990 Hoffman-LaRoche Research Center, Nutley, New Jersey 1991 Eli Lilly & Co., Indianapolis, Indiana 1991 City University of New York, New York, New York 1991 University of Cincinnati, Cincinnati, Ohio 1991 University of Colorado, Boulder, Colorado 1991 University of Missouri at Kansas, Kansas City, Missouri 1992 Williams College at Williamsburg, Massachusetts 1992 Centre College at Danville, Kentucky 1992 University of Colorado, Boulder, Colorado 1992 Eli Lilly & Co., Indianapolis, Indiana 1992 Merck Laboratories, West Point, Pennsylvania 1993 NIH Rocky Mountain Laboratory, Hamilton, MT 1993 Intern. Acad. Oral & Medical Toxicology, Chicago, IL 1993 Univ. Tenn. at Memphis, Memphis, TN 1993 Penn State University, College Station, PN 1993 University California, Riverside, Riverside, CA 1993 Mayo Clinic, Jacksonville, FL 1993 Washington University, St. Louis, MO 1993 University of Arkansas, Little Rock, AR 1994 European Academy of Science, Otzenhausen, Germany 1994 Intern. Acad. Oral & Medical Toxicology, London, England. 1994 Great Lakes College for Advancement of Medicine, Cincinnati, OH 1995 American College for the Advancement of Medicine, Colorado Springs, CO. 1995 Pfizer Pharmaceuticals, Groton, CN 1995 Ohio State University, Dept,. Chemistry, Columbus, OH 1996 Intern. Acad. Oral & Medical Toxicology, Tuscon, AZ 1996 University of Wyoming, Laramie WY 1996 American College for the Advancement of Medicine, Colorado Springs, CO. 1997 American Academy Biological Dentistry, Carmel, CA March 7-9. 1997 International Academy of Oral and Medical Toxicology, Louisville, KY March 14-16 1997 Washington State University, Dept. of Chemistry and Biophysics, Pullman, WA, March 27-30. 1997 American Society of Biochemistry and Molecular Biology, Symposium talk, August 24-28. 1997 Canadian Academy Oral and Medical Toxicology, Toronto, Canada. September 19-21. 1997 Capital University of Integrative Medicine, Washington, DC, October 16-18 1997 American Academy Environmental Medicine, San Diego, CA, October 24-26. 1997 University of Missouri at Kansas City, Dept. Biology & Biophysics, November 20-22. SERVICE TO DEPARTMENT, COLLEGE AND UNIVERSITY: 1975-1979 Faculty Senate Biological Interdepartmental Seminar Committee University Grievance Procedure Committee College of Agriculture Teaching Improvement Committee College of Agriculture Academic Planning Committee Faculty Senate Nominating Committee Division of Biochemistry Undergraduate Teaching Committee Division of Biochemistry Graduate Program Committee University Research Coordination Committee Chairman of the Graduate Committee, Biochemistry Department 1979-1982 College of Agriculture Tenure and Promotion Committee 1979 College of Agriculture Dean Search Committee 1981 Vice-President for Research Search Committee 1981 College of Human Medicine Evaluation Committee 1981-1982 Biomedical Research Funding Committee 1982 Chairman, Department of Zoology and Physiology Review Committee 1986 Research Committee College of Medicine Ad Hoc Committee to Review Center on Aging Ad Hoc Medical Center Research Advisory Committee Working Group for Biotechnology Center Center for Pharmaceutical Science and Technology Advisory Committee College of Pharmacy Graduate Program College of Pharmacy Research and Seminar 1987 Markey Cancer Center Internal Advisory Committee College of Medicine Research Committee Tobacco and Health Advisory Committee 1988 College of Pharmacy BRSG Committee, Tenure and Promotion 1989 Chairman, College of Medicine BRSG Committee Member, Tobacco & Health Advisory Committee Member, Markey Cancer Center Advisory Committee 1990 Chairman, College of Medicine BRSG Committee 1991-1992 Member, Intellectual Properties Committee Member, Search Committee Cancer Center Director Member, Cancer Center Advisory Committee Member, Search Committee Diagnostic Radiology Chair Member, Academic Area Committee, Biological Sciences 1993-1995 Chair, Research and Seminar Committee Member, Appointment, Tenure and Promotion Committee 1996-1997 Chair, Graduate Program task force, College of Pharmacy Chair, Physical Plant section, College of Pharmacy self-study University Chemical Safety Committee College of Medicine Academic Council College of Pharmacy Tenure and Promotion Committee PUBLICATIONS (REFEREED JOURNALS) 1. Haley, B. and Yount, R. Gamma-fluoradenosine Triphosphate.Synthesis, Properties and Interaction with Myosin and Heavy Meromyosin. Biochemistry II, 2863-2871 (1972). 2. Haley, B., Yount and Hoffman, J. Selective Inhibition of Divalent Metal Ion Requiring ATPase Activity of Human Red Cell Ghost by an Analog of ATP. The Physiologist 16, 333-334 (1973). 3. Haley, B. and Hoffman, J. Interactions of Photo-Affinity ATP Analog with Cation-Stimulated ATPase Activities of Human Red Cell Ghost. Proc. Natl. Acad. Sci. 71, 3367-3371 (1974). 4. Staros, J.V., Haley, B. and Richards, F.M. Human Erythrocytes and Resealed Ghost: A Comparison of Membrane Topology. J. Biol. Chem. 249, 5004-5007 (1974). 5. Pomerantz, A., Rudolph, S.A., Haley, B. and Greengard, P. Photoaffinity Labeling of a Protein Kinase from Bovine Brain with 8-Azido-adenosine-3', 5'-monophosphate. Biochemistry 14, 3852-3857 (1975). 6. Haley, B. Photoaffinity Labeling of cAMP Binding Sites of Human Red Blood Cell Membranes. Biochemistry 14, 3852-3857 (1975). 7. Staros, J.V., Richards, F.M. and Haley, B. Photochemical Labeling of the Cytoplasmic Surface of the Membranes of Intact Human Erythrocytes. J. Biol. Chem. 250, 8174-8178 (1975). 8. Malkinson, A.M., Krueger, B.V., Rudolph, S.A., Casnelli, J.E., Haley, B. and Greengard, P. Widespread Occurence of a Specific Protein in Vertebrate Tissues and Regulation by cAMP of its Endogenous Phosphorylation and Dephosphorylation. Metabolism 24, 331-341 (1975). 9. Haley, B. Photoaffinity Labeling of Adenosine 3', 5'-Cyclic Monophosphate Binding Sites. Methods in Enzymology, Jacoby and Wilchek, Editors. V 46, pp. 339-346 (1976). 10. Owens, J.R. and Haley, B.E. A Study of Adenosine 3', 5'-Cyclic Monophosphate Binding Sites of Human Erythrocyte Membranes Using 8-Azido-adenosine-3'-5' Cyclic Monophosphate. J. Supra. Mole. Structure 5, 91-102 (1976). 11. Skare, K., Black, J.L., Pancoe, W.L. and Haley, B. Determination of the Cellular Location of Cyclic Nucleotide Binding Sites Using 8-Azido-adenosine-3', 5'-monophosphate, A Photoaffinity Probe. Arch. Biochem. Biophy. 180, 409-415 (1977). 12. Lau, E., Haley, B. and Barden, R. Interactions of a Photoaffinity Analog of CoA with CoA Enzymes. Biochemistry 16, 2581-2585 (1977). 13. Owens, J.R. and Haley, B. A Study of Adenosine 3', 5'-Cyclic Nucleotide Binding Sites of Human Erythrocyte Membranes Using 8-Azido-adenosine 3'-5'-Cyclic Monophosphate. Cell Shape and Surface Architecture: Progress in Clinical and Biological Research 17, 65-76 (1977) 14. Lau, E.P., Haley, B. and Barden, R. The 8-Azidoadenine Analog of S-Benzoyl (3'-dephospho) Coenzyme A-A Photoaffinity Label for Acyl CoA; Glycine N-Acyltransferase. Biochem. Biophys. Res. Commun 76, 843-849 (1977). 15. Geahlen, R.T. and Haley, B. Interactions of a Photoaffinity Analog of GTP with the Proteins of Microtubules. Proc. Natl. Acad. Sci. 74, 4375-4377 (1977). 16. Owens, J.R. and Haley, B. Use of Photoaffinity Nucleotide Analogs to Determine the Mechanism of ATP Regulation of a Membrane Bound, cAMP Activated Protein Kinase. J. Supra. Mole. Structure 9, 57-68 (1978). 17. Czarnecki, J., Geahlen, R.T. and Haley, B. Synthesis and Use of Azido Photoaffinity Analogs of Adenine and Guanine Nucleotides. Methods in Enzymology 56, 642-653 (1979). 18. Marcus, F. and Haley, B. Inhibition of Fructose 1,6-biphosphatase by the Photoreactive AMP Analog, 8-Azido-AMP. J. Biol. Chem. 254, 259-261 (1979). 19. Geahlen, R., Haley, B. and Krebs, E.G. Synthesis and Use of 8-azidoguanosine 3', 5'-cyclic Monophosphate as a Photoaffinity Label for Cyclic GMP-dependent Protein Kinase. Proc. Natl. Acad. Sci. 76, 2213-2217 (1979). 20. Geahlen, R. and Haley, B. Use of GTP Photoaffinity Probe to Resolve Aspects of the Mechanism of Tubulin Polymerization. J. Biol. Chem. 254, 11982-11987 (1979). 21. Haley, B. Application of Photoaffinity Nucleotide Analogs to Biological Membrane Research. Selected Aspects of Cancer-Related Protein, Carbohydrate, Lipid and other Biochemistry, International Cancer Research Data Bank, p. 87 (1979). 22. Owens, J. and Haley, B. Mechanism of MgATP Regulation of Membrane Bound Type I cAMP Activated Protein Kinase. Transmembrane Signaling. Alan R. Liss, Inc. New York, New York, pp. 149-160 (1979). 23. Forrester, I.T., P.K. Schoff, B.E. Haley and R.G. Atherton. Determination of Protein Kinase Activity in Intact Mammalian Sperm. J. of Andrology 1, 70 (1980). 24. Briggs, F. Norman, Al-Jumaily, Walid and Haley, Boyd. Photoaffinity Labeling of the (Ca+Mg) ATPase of Skeletal and Cardiac Sarcoplasmic Reticulum with [32P-]-8-Azido ATP. Cell Calcium 1, 205-215 (1980). 25. Hoyer, P., Owens, J.R. and Haley, B.E. Use of Nucleotide Photoaffinity Probes to Elucidate Molecular Mechanisms of Nucleotide Regulated Phenomena. Annals of New York Academy of Science 346, 280-301 (1980). 26. Takemoto, D.J., B.E. Haley, J. Hanse, P. Pinbett and L.J. Takemoto. GTPase from Rod Outer Segments: Characterization by Photoaffinity Labeling and Tryptic Peptide Mapping. Biochem. Biophys. Res. Commun. 102, 341-347 (1981). 27. Leichtling, B.H., Coffman, D.S., Yaeger, E.S., Rickenberg, H.V., Al-Jumaily, W. and Haley, B.E. Occurrence of the Adenylate Cyclase "G-Protein" in Membranes of Dictyostelium discoidium, Biochem. Biophys. Res. Commun. 102, 1187-1195 (1981). 28. Schoff, P.K., Forester, I.T., Haley, B.E. and Atherton, R. A Study of cAMP Binding Proteins on Intact and Distrupted Sperm Cells Using 8-Azidoadenosine-3', 5'-Cyclic Monophosphate. J. Supra. Molecular Structure 19, 1-15 (1982). 29. King, M.M., Carlson, G. and Haley, B.E. Photoaffinity-Labeling of the Subunit of Phosphorylase Kinase by 8-Azidoadenosine-5'-Triphosphate and its 2', 3' -Dialdehyde Derivative. J. Biol. Chem. 257, 14058-14065 (1982). 30. Potter, R. and Haley, B.E. Photoaffinity Labeling of Nucleotide Binding Sites with 8-Azidopurine Analogs. Meth. Enzymol. 91, 613-633 (1982). 31. Hoyer, P.B. and Haley, B.E. Utilization of Nucleotide Photoaffinity Probes to Study Protein-Nucleotide Interactions in Cell Fractions. J. Cellular Biochemistry, submitted. (1983) 32. Haley, Boyd. Development and Utilization of 8-Azidopurine Nucleotide Photoaffinity Probes. Federation Proceedings 42, 2831-2836 (1983). 33. Khatoon, S., Atherton, R. Al-Jumaily, W. and Haley, B.E. Use of Nucleotide Photoaffinity Probes to Study Hormone Action. Biology of Reproduction 28, 61-73 (1983). 34. Kaiser, I.I., Kladianos, D.M., Van Kirk, E.A., and Haley, B.E. Photoaffinity Labeling of catechol-o-methyltransferase with 8'-Azido-S-adenosylmethionine. J. Biol. Chem. 258, 1747-1751 (1983). 35. Abraham, K., Haley, B. and Modak, M. Biochemistry of Terminal Deoxynucleotidyl Transferase: 8-Azido ATP as A Substrate Binding Site-Directed Photoaffinity Labeling Prob. Biochemistry 22, 4197-4203 (1983). 36. Haley, B.E., Ponstingl, H. and Doenges, K.H. Photoaffinity Labeling of Pure Tubulin Using 8-Azidoguanosine triphosphate at the b-Subunit. Hoppe-Seylers J. Physiol. Chem. 364, 1137 (1983). 37. Woody, A.M., Vader, C.R., Woody, R.W. and Haley, B.E. Photoaffinity Labeling of DNA-dependent RNA polymerase from E. coli with 8-azidoadenosine-5'-triphosphate. Biochemistry 23, 2843-2848 (1984). 38. Owens, J.R. and Haley, B.E. Synthesis and Utilization of [5'-32P]-8-Azidoguanosine-3'-phosphate-5'-phosphate: Photoaffinity Studies on Cytosolic Proteins of E. coli. J. Biol. Chem. 259, 14843-14848 (1984). 39. Pfister, K.K. , Haley, B.E. and Witman, G.B. The Photoaffinity Probe 8-azidoadenosine-5'-triphosphate. Selectivity Labels the Heavy Chain of Chlamydomonas 12S Dynein. J. Biol. Chem. 259, 8499-8504 (1984). 40. Atherton, R.W., Khatoon, S., Schoff, P.K. and Haley, B.E. A Study of Rat Epididymal Sperm Adenosine-3', 5'-monophosphate-dependent Protein Kinase: Maturation Differences and Cellular Location. Biol. of Reproduction 32, 155-172 (1985). 41. McMurray, M.M., Hansen, J.S., Haley, B.E., Takemoto, D.J. and Takemoto, L.J. Interspecies Conservation of Retinal Guanosine-5'-triphosphatase: Characterization by Photoaffinity Labeling and Tryptic Peptide Mapping. Biochemical Journal 225, 227-232 (1985). 42. Khatoon, S., Haley, B.E. and Atherton, R.W. A Comparative Analysis of cAMP-dependent Protein Kinase Regulatory Subunits in Sea Urchin and Rat Sperm. J. Andrology 6, 251-260 (1985). 43. DeBortoli, M.E., Issa, H.A., Haley, B.E. and Cho-Chung, Y.S. Elevated Levels of p2l ras Protein in Hormone-Dependent Mammary Carcinomas of Humans and Rodents. Bioch. Biophys. Res. Commun. 127, 699-709 (1985). 44. Evans, R., Haley, B. and Roth, D. Photoaffinity Labeling of a Viral Induced Protein from Tobacco. J. Biol. Chem. 260, 7800-7804 (1985). 45. Nunamaker, R.A., Wilson, W.T. and Haley, B.E. Electrophoretic Detection of Africanized Honey Bees (Apis mellifera scutellata) in Guatemala and Mexico Based on Malate Dehydrogenase Allozyme Patterns. Journal of the Entomological Society 57, 622-631 (1985). 46. Pfister, K.K., Haley, B.E. and Witman, G.B. Labeling of Chlamydomonas 18S Dynein Polypeptides by 8-Azidoadenosine 5'-Triphosphate, a Photoaffinity Analog of ATP. J. Biol. Chem. 260, 12844-12850 (1985). 47. Hoyer, P.B., Fletcher, P. and Haley, B.E. Synthesis of 2', 3'-0-(2,4,6,-trinitrocyclohexadienylidine) guanosine 5'-Triphosphate and study of its Inhibitory Properties with Adenylate Cyclase. Arch. Biochem. Biophys. 245, 368-378 (1986). 48. Evans, R.K., Johnson, J.D. and Haley, B.E. 5'-Azido-2'-deoxyuridine-5'-triphosphate: A Novel Photoaffinity Labeling Reagent and Tool for the Enzymatic Synthesis of Photoactive DNA. Proc. Natl. Acad. Sci. USA. 83, pp. 5382-5386 (1986). 49. Jeganathan, A., Richardson, S.K., Mani, R.S., Haley, B.E. and Watt, D.S. Selective Reactions of Azide-substituted a-Diazoamides with Olefins and Alcohols Using Rhodium (II) Catalysts. J. Org. Chem. 51, 5362-5367 (1986). 50. Malkinson, A.M., Haley, B.E., Macintyre, B.E. and Buthy, M.S. Changes in Pulmonary Adenosine Triphosphate Binding Proteins Detected by Nucleotide Photoaffinity Labeling Following Treatment of Mice with the Tumor-Modulatory Agent Butylated Hydroxytoluene. Cancer Res. 46, 4626-4630 (1986). 51. Evans, R.K. and Haley, B.E. Synthesis and Biological Properties of 5-Azido-2'-deoxyuridine-5'-triphosphate: A Photoactive Nucleotide Suitable for Making Light Sensitive DNA. Biochemistry 26, 269-276 (1987). 52. Richardson, S.K., Jeganathan, A., Mani, R.S., Haley, B.E. and Watt, D.S. Synthesis and Biological Activity of C-4 and C-15 Aryl Azide Derivatives of Anguidine. Tetrahedron Letters 43, 2925 (1987). 53. Droms, K.A., Haley, B.E. and Malkinson, A.M. Decreased Incorporation of the Photoaffinity Probe [g3232P]-8N3 GTP into a 45KD Protein in Lung Tumors. Bioch. Biophys. Res. Commun. 144, 591-597 (1987). 54. Karpel, R.L., Levin, V.Y. and Haley, B.E. Photoaffinity Labeling of T4 Bacteriophage 32Protein. J.Biol.Chem. 262, 9359-66 (1987). 55. Suhadolnik, R.J., Li, Shi Wu, Sobol, Jr. R.W., and Haley, B.E. 2-and 8-Azido Photoaffinity Probes. II. Studies on the Binding Process of 2-5A Synthetase. Biochemistry 27, 8846-8851 (1988). 56. Suhadolnik, R.J., Kariko, K., Sobol, Jr., R.W., Shi Wu, Richenbach, N.L. and Haley, B.E. 2- and 8-Azido Photoaffinity Probes. I. Enzymatic Synthesis, Characterization and Biological Properties of 2- and 8-Azido Photoprobes of 2-5A & Photolabeling of 2-5A Binding Proteins. Biochemistry 27, 8840-8846 (1988). 57. Droms, K.A., Haley, B.E., Smith, G.J. and Malkinson, A.M. Decreased Photolabeling of Gsa With [a-32P]8N3-GTP in Tumorigenic Lung Epithelial Cell Lines: Association with Decreased Hormone Responsiveness and Loss of Contact-Inhibited Growth. Experimental Cell Research 182, 330-339 (1989). 58. Francis, B., Overmeyer, J., John, W., Marshall, E. and Haley, B. Prevalence of Nucleoside Diphosphate Kinase Autophosphorylation in Human Colon Carcinoma versus Normal Colon Homogenates. Molecular Carcinogenesis 2, 168-178 (1989). 59. King, S.M., Haley, B.E. and Witman, G.B. Structure of the a and b Heavy Chains of the Outer Arm Dynein from Chlamydomonas Flagella. J. Biol. Chem. 264, 10210-10218 (1989). 60. Khatoon, S., Campbell, S.R., Haley, B.E. and Slevin, J.T. Aberrant GTP b-Tubulin Interaction in Alzheimer's Disease. Annals of Neurology 26, 210-215 (1989). 61. Lawson, S.G., Mason, T.L., Sabin, R.D., Sloan, M.E., Drake, R.R., Haley, B.E. and Wasserman, B.P. UDP-Glucose: (1,3)-B-Glucan Synthase from Daucas carota L.: Characterization, Photoaffinity Labeling and Solubilization. Journal of Plant Physiology 90, 101-108 (1989). 62. Lewis, C.T., Haley, B.E. and Carlson, G.M. Formation of an Intramolecular Cystine Disulfide During the Reaction of 8-Azido-GTP with Cytosolic Phosphoenolpyruvate Carboxykinase (GTP) Causes Inactivation without Photolabeling. Biochemistry 28, 9248-9255 (1989). 63. Ho, L.T., Nie, Z.M., Mende, T.J., Richardson, S., Chavan, A., Kolaczkowska, E., Watt, D.S., Haley, B.E. and Ho, R.J. Modification of Adenylate Cyclase by Photoaffinity Analogs of Forskolin. J. Second Messengers and Phosphoproteins 12, 209-223 (1989). 64. Wasserman, B.P., Read, S.M., Frost, D.J., Mason, T.L., Drake, R.R. and Haley, B.E. Potential use of Affinity Labels in Subunit Identification Studies of (1,3)-b-Glucan Synthase. J.Applied Polymer Science Symposium (Proceeding of the Tenth Cellulose Conference, Syracuse, NY). C. Schuerch and T. Timell, Eds. 43, 827-837 (1989). 65. Drake, R.R., Evans, R.K., Wolf, M.J. and Haley, B.E. Synthesis and Properties of 5-Azido-UDP-Glucose: Development of Photoaffinity Probes for Nucleotide Diphosphate Sugar Binding Sites. J. Biol. Chem. 264, 11928-11933 (1989). 66. Dholakia, J.N., Francis, B.R., Haley, B.E. and Wahba, A. Photoaffinity Labeling of the Rabbit Reticulocyte Guanine Nucleotide Exchange Factor and Eukaryotic Initiation Factor 2 with 8-Azidopurine Nucleotides. J. Biol. Chem. 264, 20638-20642 (1989). 67. Campbell,S., Kim, H., Doukas, M. and Haley, B. Photoaffinity Labeling of ATP and NAD+ Binding Sites on Recombinant Human Interleukin-2. Proc. Natl. Acad. Sci. 87, 1243-1246 (1990). 68. Kim, H. and Haley, B. Synthesis and Properties of 2-Azido-NAD+: A Study of Interactions with Glutamate Dehydrogenase. J. Biol. Chem. 265, 3636-3641 (1990). 69. Drake, R., Palamarczyk, G., Haley, B. and Lennarz, W.J. Evidence for the Involvement of a 35-kDa Membrane Protein in the Synthesis of Glucosylphosphoryldolichol. Bioscience Reports 10, 61-68 (1990). 70. Marchase, R.B., Richardson, K.L., Srisomsap, C., Drake, R. and Haley, B.E. Resolution of Phosphoglucomutase and the 62 kDa Acceptor for the Glucosylphosphotransferase. Arch. Biochim. Biophys. 280, 122-129. (1990). 71. Salvucci, M.E. and Haley, B.E. Photoaffinity Labeling of Ribulose Bisphosphate Carboxylase/Oxygenase With 8-Azidoadenosine 5'-Triphosphate. Planta 181, 287-295 (1990). 72. Salvucci, M.E., Drake, R., Broadbent, K.P., Haley, B.E., Hanson, K.R. and McHale, N.A. Identification of the 64 Kilodalton Chloroplast Stromal Phosphoprotein as Phosphoglucomutase. Plant Physiology 93, 105-109 (1990). 73. Frost, D.J., Read, S.M., Drake, R., Haley, B.E. and Wasserman, B.P. Identification of the UDPG Binding Polypeptide of (1,3)-b-Glucan Synthase From A Higher Plant by Photoaffinity Labeling with 5-AzidoUDP-Glucose. J. Biol. Chem. 265, 2162-2167 (1990). 74. Lin, F.C., Brown, R.M. Jr., Drake, R.R. and Haley, B.E. Characterization of Cellulose Synthase Catalytic Subunit of Acetobacter xylinum Using 5-Azido-UDP-glc, A Photoaffinity Probe. J. Biol. Chem. 265, 4782-4784 (1990). 75. Salvucci, M.E., Drake, R.R., and Haley, B.E. Purification and Photoaffinity Labeling of Sucrose Phosphate Synthase from Spinach Leaves. Arch. Biochem. Biophys. 281, 212-218 (1990). 76. Chavan, A.J., Kim, H., Haley, B.E., and Watt, D.S. A Photoactive Phosphonamide Derivative of GTP for the Identification of the GTP Binding Domain of b-Tubulin. Bioconjugate Chemistry, 1, No. 5, 337-344 (1990). 77. Kwiatkowski, S., Crocker, P.J., Chavan, A.J., Nobuyuki, I., Haley, B.E. and Watt, D.S. Thiazolidine and Thiazoline Derivatives of 3-Aryl 3-Trifluormethyl Diazirines for the Preparation of Fluorescent or 35S-Radiolabeled Photoaffinity Probes. Tetrahedron Lett, 31, 2093-2096 (1990). 78. Palamarczyk, G., Drake, R., Haley, B. and Lennarz, W.J. Evidence that the Synthesis of Glucosylphosphoryl Dolichol in Yeast Involves a 35 kDa Membrane Protein. Proc. Natl. Acad. Sci. 87, 2666-2670 (1990). 79. King, S., Kim, H., and Haley, B. Strategies and Reagents for Photoaffinity Labeling of Mechanochemical Proteins. Meth. Enzymol. 196, 449-466 (1991). 80. Kim, H. and Haley, B. Identification of Peptides in the Adenine Ring Binding Domain of Glutamate and Lactate Dehydrogenase Using 2-AzidoNAD+. Bioconjugate Chemistry 2, 1142-147 (1991). 81. Mann, D., Haley, B., and Greenberg, R. Photoaffinity Labeling of Atrial Natriurtic Factor Analog Atriopeptin III woith [g32P]8N3GTP. Peptide Research 4, #2, 79-83 (1991). 82. Drake, R.R., Zimniak, P., Haley, B.E., Lester, R., Elbein, A.D. and Radominska, A. Synthesis and Characterization of5-Azido-UDP-Glucuronic Acid. J. Biol. Chem., 266, 23257-23260 (1991). 83. Drake, R.R., Zimniak, P., Haley, B.E., Lester, R., Elbein, A.D. and Radominska, A. Synthesis and Characterization of5-Azido-UDP-Glucuronic Acid. J. Biol. Chem., 266, 23257-23260 (1991). 84. Hiestand, D., Haley, B., and Kindy, M. Role of Calcium inInactivation of Calcium/Calmodulin Dependent Protein Kinase II After Cerebral Ischemia. Journal of the Neurological Sciences, 113, 31-37 (1992). 85. Salvucci, M., Chavan, A. and Haley, B. Identification of Peptides for the Adenine Binding Domains of ATP and AMP in Adenylate Kinase: Isolation of Photoaffinity Labeled Peptides by Metal Chelate Chromatography. Biochemistry 31 4479-4487 (1992). 86. Shoemaker, M., Lin, P.C., and Haley, B. Identification of the Guanine Binding Domain Peptide of the GTP Binding Site of Glucagon. Protein Science 1, 884-891 (1992). 87. Doukas, M., Chavan, A., Gass, C., Boone, T. and Haley, B. Identification and charaterization of a Nucleotide Binding Site on Recombinant Murine Granulocyte/Macrophage-Colony Stimulating Factor. Bioconjugate Chemistry 3, 484-492 (1992). 88. Segal, A., West, I., Wientjes, F., Nugent, J., Chavan, A., Haley, B., Garcia, R., Rosen, H. and Scrace, G. Cytochrome b-245 is a Flavocytochrome Containing FAD and the NADPH Binding Site of the Microbicidal Oxidase of Phagocytes. Biochem. J. 284, 781-788 (1992). 89. Hammond, D., Haley, B. and Lesnaw, J. Identification and Characterization of Serine/Threonine Protein Kinase ActivityIntrinsic to the L Protein of Vesicular Stomatitis Virus New Jersey. Journal of General Virology 73, 67-75 (1992) 90. Chavan, A., Nemoto, Y., Narumiya, S., Kozaki, S., and Haley, B. NAD+ Binding Site of Clostridium botulinum C3 ADP-ribosyltransferase: Identification of Peptide in the Adenine Ring Binding Domain using 2-Azido NAD+. J. Biol. Chem. 267, 14866-14870 (1992). 91. Gunnersen, D.J. and Haley, B.E. Detection of Glutamine Synthetase in the Cerebrospinal Fluid of Alzheimer's Diseased Patients: A Potential Diagnostic Biochemical Marker. Proc. Natl. Acad. Sci. USA, 89 pp. 11949-11953 (1992). 92. Shoemaker, M., and Haley, B. Identification of a Guanine Binding Domain Peptide of the GTP Binding Site of Glutamate Dehydrogenase: Isolation with Metal-Chelate Affinity Chromatography. Biochemistry 32, 1883-1890 (1993). 93. Churn, S.B., Sankaran, B., Haley, B.E. and Delorenzo, R.J. Ischemic Brain Injury Selectively Alters ATP Binding of Calcium and Calmodulin-Dependent Protein Kinase-II. Biochem. Biophys. Res. Comm. 193:3, 934-940 (1993). 94. Salvucci, M., Rajagopalan, K., Sievert, G., Haley, B. and Watt, D. Photoaffinity Labeling of Rubisco Activase with ATP-g-benzophenone: Identification of the ATP g-Phosphate Binding Domain J. Biol. Chem. 268, 14239-14244 (1993). 95. Rajagopalan, K., Chavan, A., Haley, B. and Watt, D. Bidentate Cross-Linking Reagents: Non-Hydrolyzable Nucleotide Photoaffinity Probes with Two Photoactive Groups J. Biol. Chem. 268, 14245-14253 (1993). 96. Trad, C., Chavan, A., Clemens, J., and Haley, B. Identification and Characterization of an NADH Binding Site of Prolactin with 2-Azido-NAD+ Arch. Biochem. Biophys. 304, 58-64 (1993). 97. Chavan, A., Ensor, C., Wu, P., Haley, B. and Tai, H. Photoaffinity Labeling of Human Placental NAD+-Linked 15-Hydroxyprostaglandin Dehydrogenase with [a32P]-2N3NAD+: Identification of a Peptide in the Adenine Ring Binding Domain J. Biol. Chem. 268, 16437-16442 (1993). 98. Chavan, A., Richardson, S., Kim, H., Haley, B. and Watt, D. Forskolin Photoaffinity Probes for the Evaluation of Tubulin Binding Sites Bioconjugate Chem. 4, 268-274 (1993). 99. Duhr, E.F., Pendergrass, J. C., Slevin, J.T., and Haley, B. HgEDTA Complex Inhibits GTP Interactions With The E-Site of Brain b-Tubulin Toxicology and Applied Pharmacology 122, 273-288 (1993). 100. Jayaram, B. and Haley, B. Identification of Peptides Within the Base Binding Domains of the GTP and ATP Specific Binding Sites of Tubulin. J. Biol. Chem. 269 (5) 3233-3242 (1994). 101. A. Chavan, B. Haley, D. Volkin, K. Marfia, A. Verticelli, M. Bruner, J. Draper, C. Burke and R. Middaugh. Interaction of Nucleotides with Acidic Fibroblast Growth Factor (FGF-1). Biochemistry 33,7193-7202 (1994). 102. Logan, J., Hiestand, D., Daram, P., Huang, Z., Muccio, D., Hartman, J., Haley, B., Cook, W., and Sorscher, E. Cystic Fibrosis Transmem |
Enable EMail Alerts
Start New Thread
Reply to this Message